Showing results (1-10 of 75) with videos related to
Sort By:
Pageof 8
Expert Review of Vaccines|August 3, 2011
Using monoclonal antibodies to stimulate antitumor cellular immunityLindy G Durrant, Victoria A Pudney, Ian SpendloveOncoimmunology|March 5, 2016
Cancer cell associated glycans as targets for immunotherapyMireille Vankemmelbeke, Jia Xin Chua, Lindy G DurrantAutophagy|May 5, 2016
Autophagy, citrullination and cancerLindy G Durrant, Rachael L Metheringham, Victoria A BrentvilleBiomedicines|March 24, 2018
Current Strategies to Enhance Anti-Tumour ImmunityKatherine W Cook, Lindy G Durrant, Victoria A BrentvilleExpert Opinion on Biological Therapy|April 14, 2010
Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responsesLindy G Durrant, Victoria Pudney, Ian Spendlove, et al.Therapeutic Advances in Vaccines and Immunotherapy|July 13, 2018
Novel tumour antigens and the development of optimal vaccine designVictoria A Brentville, Suha Atabani, Katherine Cook, et al.Plos One|February 15, 2013
Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29Philip Noble, Ian Spendlove, Stephen Harding, et al.Frontiers in Immunology|April 16, 2021
Cancer Vaccines, Adjuvants, and Delivery SystemsSamantha J Paston, Victoria A Brentville, Peter Symonds, et al.Plos One|July 26, 2012
High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairmentVictoria A Brentville, Rachael L Metheringham, Barbara Gunn, et al.Cancer Immunology, Immunotherapy : CII|February 18, 2006
Complement decay accelerating factor (DAF)/CD55 in cancerIan Spendlove, Judith M Ramage, Richard Bradley, et al.Pageof 8